CSTL
$25.90
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Recent News
CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data
CytomX Therapeutics stock surges 44% after phase I data for Varseta-M in heavily pretreated metastatic CRC show rising response rates and strong disease control.
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU
AZN wins the EU nod for Imfinzi in early gastric and GEJ cancers, backed by strong survival data and expanding its blockbuster oncology footprint.
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
Beam Therapeutics Stock Surges 23% in 6 Months: What's Driving It?
BEAM shares jump 23% in six months as upbeat risto-cel data, pipeline expansion and new financing strengthen confidence in its gene-editing strategy.
How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value
Castle Biosciences’ updated fair value moves slightly from US$48.57 to US$48.50 per share, a small shift that still reflects the latest round of analyst work on the name. That change is tied to recent research that raised revenue assumptions for 2025 and beyond and supported higher published price targets that feed into the US$48.50 figure. As you read on, you will see how these fresh targets, both bullish and cautious, shape the evolving narrative around Castle Biosciences and what it could...